Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Early Initiation of Treatment with Copaxone (R) Provides Greater Effects in Delaying Conversion to Clinically Definite MS
Early Initiation of Treatment with Copaxone (R) Provides Greater Effects in Delaying Conversion to Clinically Definite MS
Early Initiation of Treatment with Copaxone (R) Provides Greater Effects in Delaying Conversion to Clinically Definite MS
Submitted by
admin
on October 16, 2010 - 9:41am
Source:
Trading Markets
News Tags:
Copaxone
multiple sclerosis
Teva Pharmaceuticals
Headline:
Early Initiation of Treatment with Copaxone (R) Provides Greater Effects in Delaying Conversion to Clinically Definite MS
Do Not Allow Advertisers to Use My Personal information
